Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: A prospective evaluation in SWOG and LYSA studies

Journal of Clinical Oncology

Volumn 33, Issue 13, 2015, Pages 1482-1490

  Kelly, Jennifer L ^a   Salles, Gilles ^b   Goldman, Bryan ⁱ   Fisher, Richard I ^j   Brice, Pauline ^c   Press, Oliver ⁱ   Casasnovas, Olivier ^d   Maloney, David G ^h   Soubeyran, Pierre ^e   Rimsza, Lisa ^k   Haioun, Corinne ^f   Xerri, Luc ^g   LeBlanc, Michael ⁱ   Tilly, Hervé ^h   Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITÉ LYON 1   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e INSTITUT BERGONIÉ   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h CENTRE HENRI BECQUEREL   (France)

ⁱ USA   (United States)

^j TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE; VITAMIN D; 25-HYDROXYVITAMIN D; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); EVALUATION STUDY; FEMALE; FOLLICULAR LYMPHOMA; GOLD STANDARD; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; ANALOGS AND DERIVATIVES; BLOOD; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME FACTOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; CHROMATOGRAPHY, LIQUID; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; RITUXIMAB; TANDEM MASS SPECTROMETRY; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84929429229     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.5092     Document Type: Article

References (32)

1. Schwartz GG, Skinner HG: Vitamin D status and cancer: New insights. Curr Opin Clin Nutr Metab Care 10:6-11, 2007
2. Robsahm TE, Schwartz GG, Tretli S: The Inverse relationship between 25-hydroxyvitamin D and cancer survival: Discussion of causation. Cancers (Basel) 5:1439-1455, 2013
3. Kelly JL, Friedberg JW, Calvi LM, et al: Vitamin D and non-Hodgkin lymphoma risk in adults: A review. Cancer Invest 27:942-951, 2009
4. Consolini R, Pala S, Legitimo A, et al: Effects of vitamin D on the growth of normal and malignant B-cell progenitors. Clin Exp Immunol 126:214-219, 2001
5. Hickish T, Cunningham D, Colston K, et al: The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer 68:668-672, 1993
6. Drake MT, Maurer MJ, Link BK, et al: Vitamin D deficiency is associated with inferior event-free and overall survival in diffuse large B-cell lymphoma. J Clin Oncol 28:4191-4198, 2010
7. Bittenbring JT, Neumann F, Altmann B, et al: Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 32:3242-3248, 2014
8. Shanafelt TD, Drake MT, Maurer MJ, et al: Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia (CLL). Blood 117:1492-1498, 2011
9. Maloney DG, Pender-Smith B, Unger JM, et al: Fc{gamma} receptor polymorphisms do not influence progression free survival (PFS) of follicular NHL pateints treated with CHOP followed by rituximab (SWOG 9800). Blood 104, 2004 (abstr 589)
10. Press OW, Unger JM, Braziel RM, et al: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Fiveyear follow-up of SWOG Protocol S9911. J Clin Oncol 24:4143-4149, 2006
11. Press OW, Unger JM, Rimsza LM, et al: Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 31:314-320, 2013
12. Press OW, Unger JM, Rimsza LM, et al: A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine-tositumomab. Clin Cancer Res 19:6624-6632, 2013
13. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
14. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
15. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
16. Mayo Clinic: Reference laboratory services for health care organizations. http://www.mayomedicallaboratories.com
17. Hollis BW: Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the clinical environment. Endocrinol Metab Clin North Am 39:271-286, 2010
18. Holick MF, Siris ES, Binkley N, et al: Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90:3215-3224, 2005
19. Wang Y, Jacobs EJ, McCullough ML, et al: Comparing methods for accounting for seasonal variability in a biomarker when only a single sample is available: Insights from simulations based on serum 25-hydroxyvitamin D. Am J Epidemiol 170:88-94, 2009
20. Institute of Medicine: Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC, National Academies Press, 2011
21. Lips P: Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 89-90:611-614, 2004
22. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
23. Łuczyńska A, Kaaks R, Rohrmann S, et al: Plasma 25-hydroxyvitamin D concentration and lymphoma risk: Results of the European prospective investigation into cancer and nutrition. Am J Clin Nutr 98:827-838, 2013
24. Zgaga L, Theodoratou E, Farrington SM, et al: Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol 32:2430-2439, 2014
25. Zgaga L, Theodoratou E, Farrington SM, et al: Diet, environmental factors, and lifestyle underlie the high prevalence of vitamin D deficiency in healthy adults in Scotland, and supplementation reduces the proportion that are severely deficient. J Nutr 141:1535-1542, 2011
26. Powe CE, Evans MK, Wenger J, et al: Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 369:1991-2000, 2013
27. Holick MF: Bioavailability of vitamin D and its metabolites in black and white adults. N Engl J Med 369:2047-2048, 2013
28. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in the United States: First report of the national LymphoCare study. J Clin Oncol 27:1202-1208, 2009
29. Uchida J, Hamaguchi Y, Oliver JA, et al: The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199:1659-1669, 2004
30. Neuhouser ML, Manson JE, Millen A, et al: The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol 175:673-684, 2012
31. Kahl B: Is there a role for "watch and wait" in follicular lymphoma in the rituximab era? Hematology Am Soc Hematol Educ Program 2012:433-438, 2012
32. Friedberg JW: End of rituximab maintenance for low-tumor burden follicular lymphoma. J Clin Oncol 32:3093-3095, 2014